Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 12/20 | 1.00 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25435582 | 1.00 | UGCG (1.00) | UGCGCNR1CNR2STAT1CHRNA3 | |
| SCHEMBL25435154 | 0.93 | UGCG (1.00) | UGCGCNR1CNR2CHRNA3 | |
| SCHEMBL30589708 | 0.90 | UGCG (0.84) | UGCGCNR1CNR2CHRNA3HTR3A | |
| SCHEMBL25435318 | 0.90 | UGCG (0.84) | UGCGCNR1CNR2CHRNA3HTR3A | |
| SCHEMBL30589714 | 0.90 | UGCG (1.00) | UGCGCNR1CNR2 | |
| SCHEMBL25436144 | 0.90 | UGCG (1.00) | UGCGCNR1CNR2 | |
| SCHEMBL30589707 | 0.87 | UGCG (0.78) | UGCGCNR1CNR2HTR3A | |
| SCHEMBL25435053 | 0.87 | UGCG (0.78) | UGCGCNR1CNR2HTR3A | |
| SCHEMBL25437295 | 0.85 | UGCG (1.00) | UGCGCHRNA3HTR3A | |
| SCHEMBL25437725 | 0.85 | UGCG (0.79) | UGCGCNR1CNR2CHRNA3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171467-A1 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | claimed |
| EP-4493545-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2023177563-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-21 | — | — | WO | claimed |
| US-20250171467-A1 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4493545-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023177563-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171467-A1 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | UGCG 8/4885CNR1 1431/4885CNR2 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.